152 related articles for article (PubMed ID: 22890443)
21. Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer.
Marotta V; Sciammarella C; Capasso M; Testori A; Pivonello C; Chiofalo MG; Gambardella C; Grasso M; Antonino A; Annunziata A; Macchia PE; Pivonello R; Santini L; Botti G; Losito S; Pezzullo L; Colao A; Faggiano A
J Clin Endocrinol Metab; 2017 Feb; 102(2):661-671. PubMed ID: 27849428
[TBL] [Abstract][Full Text] [Related]
22. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
[TBL] [Abstract][Full Text] [Related]
23. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma.
Karaca Z; Tanriverdi F; Unluhizarci K; Ozturk F; Gokahmetoglu S; Elbuken G; Cakir I; Bayram F; Kelestimur F
Eur J Endocrinol; 2011 Feb; 164(2):277-84. PubMed ID: 21097568
[TBL] [Abstract][Full Text] [Related]
24. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
[TBL] [Abstract][Full Text] [Related]
25. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.
Klein M; Vignaud JM; Hennequin V; Toussaint B; Bresler L; Plénat F; Leclère J; Duprez A; Weryha G
J Clin Endocrinol Metab; 2001 Feb; 86(2):656-8. PubMed ID: 11158026
[TBL] [Abstract][Full Text] [Related]
27. Thyroglobulin - what is the postoperative threshold for the suspicion of thyroid cancer recurrence in the absence of anti-Tg antibody measurement?
Papageorgiou MS; Liratzopoulos N; Minopoulos G; Manolas KJ
S Afr J Surg; 2011 Aug; 49(3):118-22. PubMed ID: 21933495
[TBL] [Abstract][Full Text] [Related]
28. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
Pelttari H; Välimäki MJ; Löyttyniemi E; Schalin-Jäntti C
Eur J Endocrinol; 2010 Nov; 163(5):757-63. PubMed ID: 20813788
[TBL] [Abstract][Full Text] [Related]
29. Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung.
Kim M; Kim WG; Park S; Kwon H; Jeon MJ; Lee JJ; Ryu JS; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Jan; 27(1):49-58. PubMed ID: 27750021
[TBL] [Abstract][Full Text] [Related]
30. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
[TBL] [Abstract][Full Text] [Related]
31. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
[TBL] [Abstract][Full Text] [Related]
32. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
33. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
Kukulska A; Krajewska J; Kołosza Z; Paliczka-Cies Lik E; Puch Z; Gubała E; Król A; Kalemba M; Kropin Ska A; Jarząb B
Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823
[TBL] [Abstract][Full Text] [Related]
34. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract][Full Text] [Related]
36. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
37. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
Mousa U; Yikilmaz AS; Nar A
Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
[TBL] [Abstract][Full Text] [Related]
38. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
39. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
40. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
